Impact of Helicobacter pylori Infection on the Humoral Immune Response to MUC1 Peptide in Patients with Chronic Gastric Diseases and Gastric Cancer
Impact of Helicobacter pylori Infection on the Humoral Immune Response to MUC1 Peptide in Patients with Chronic Gastric Diseases and Gastric Cancer
复制标题
DOI：
10.1080/08820130601109727
复制
发表时间：
2007-01
影响因子：
2.8
通讯作者：
K. Klaamas;O. Kurtenkov;S. Mensdorff-Pouilly;L. Shljapnikova;L. Miljukhina;Vadim Brjalin;A. Lipping
中科院分区：
文献类型：
--
作者：
K. Klaamas;O. Kurtenkov;S. Mensdorff-Pouilly;L. Shljapnikova;L. Miljukhina;Vadim Brjalin;A. Lipping
许多研究者已经证实H. pylori感染者。H. pylori感染导致MUC 1糖基化异常和核心肽MUC 1表位的解蔽可增强对MUC 1的免疫应答。以牛血清白蛋白-MUC 160肽为抗原，用ELISA法检测了214例胃癌、160例慢性胃十二指肠疾病和91例健康献血员对MUC 1 IgG和IgM的免疫应答。H. pylori血清学状态用ELISA和CagA状态用免疫印迹法评估。根据悉尼评分系统对胃粘膜组织学进行评分。与H相比。pylori血清阴性者，H. pylori阳性的胃良性疾病患者（P < 0.01）和献血员（P < 0.03）。在慢性胃十二指肠疾病患者中，较高的MUC 1 IgG抗体水平与较高程度的胃体粘膜炎症相关（p < 0.0025）。抗H抗体水平与肝硬化患者血清中抗H抗体水平呈正相关。幽门螺杆菌IgG和MUC 1 IgG抗体水平在献血者中（p = 0.03），和在良性疾病患者中（p < 0.0001）。在胃癌患者（n = 214）中，观察到抗MUC 1 IgG的水平显著高于献血员（p < 0.001），与H.幽门螺杆菌状态或癌症阶段。MUC 1 IgM抗体水平与H.幽门血清学。IgG免疫应答肿瘤相关MUC 1上调H. pylori感染者。这种增加与对H.幽门螺杆菌感染和胃粘膜炎症程度较高。高水平的MUC 1 IgG抗体，与H.幽门螺杆菌血清学状态是胃癌患者的特征。研究结果表明，在某些个体中，H。pylori感染可刺激对肿瘤相关MUC 1肽抗原的免疫应答，从而调节肿瘤免疫。
Many investigators have demonstrated alteration of gastric mucins in H. pylori infected individuals. The inflammatory environment induced by H. pylori leading to aberrant glycosylation of MUC1 and demasking of core peptide MUC1 epitope could enhance immune responses to MUC1. IgG and IgM immune response to MUC1 in patients with gastric cancer (n = 214) chronic gastroduodenal diseases (n = 160) and healthy blood donors (n = 91) was studied with ELISA using bovine serum albumin-MUC1 60-mer peptide as antigen. H. pylori serologic status was evaluated with ELISA and CagA status by immunoblotting. Gastric mucosa histology was scored according to the Sydney system. Compared to H. pylori seronegative individuals, higher levels of IgG antibody to MUC1 were found in H. pylori seropositive patients with benign gastric diseases (p < 0.01) and blood donors (p < 0.03). Higher MUC1 IgG antibody levels were associated with a higher degree of gastric corpus mucosa inflammation in patients with chronic gastroduodenal diseases (p < 0.0025). There was a positive correlation between the levels of anti-H. pylori IgG and MUC1 IgG antibody levels in blood donors (p = 0.03), and in patients with benign diseases (p < 0.0001). In patients with gastric cancer (n = 214) a significantly higher level of anti-MUC1 IgG than in blood donors was observed (p < 0.001) irrespective of H. pylori status or stage of cancer. MUC1 IgM antibody levels were not related to the H. pylori serology. IgG immune response to tumor-associated MUC1 is up regulated in H. pylori infected individuals. This increase is associated with a higher IgG immune response to H. pylori and with a higher degree of gastric mucosa inflammation. High levels of MUC1 IgG antibody irrespective of H. pylori serologic status characterized patients with gastric cancer. The findings suggest that, in some individuals, the H. pylori infection may stimulate immune response to tumor-associated MUC1 peptide antigen thus modulating tumor immunity.